
    
      The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from
      5 medical centers in China. All participants receive dexamethasone (given orally at a dose of
      40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once),
      cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous
      immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment
      of adults newly diagnosed ITP patients.
    
  